Sahlgrenska Universitetssjukhuset

As part of the ASSET innovation partnership led by Diamyd Medical, the Leading Healthcare Foundation organizes a conference on November 26, 2024, in Stockholm, Sweden, on the future of Type 1 Diabetes screening and treatment. The conference is co-sponsored by Sanofi. The event gathers key stakeholders, including patient organizations, healthcare professionals, researchers, and regulators, to explore the practical implementation of precision and preventive medicine in Type 1 Diabetes care. The conference will feature a keynote lecture by Prof. Chantal Mathieu, President of the European Association for the Study of Diabetes (EASD), and leading expert in diabetes care, who will discuss ongoing screening initiatives and guidelines in Europe. Additionally, two panel discussions will bring together patient and professional organizations, clinicians, regulators and policymakers. These discussions will center on the ethical, regulatory and policy requirements needed to integrate new screening technologies and innovative precision medicine therapies into the healthcare system. “Together with our ASSET partners and Sanofi, we are excited to expand the conversation on how early diagnosis and innovative approaches in precision medicine can transform Type 1 Diabetes care,” says Ulf Hannelius, CEO of Diamyd Medical. “By working together, we can drive the changes needed to make early diagnosis and precision treatment for Type 1 Diabetes a reality.” For more details and to register for the event, please visit https://leadinghealthcare.se/kalendern/framtidens-screening-konferens/. About ASSET The innovation milieu ASSET (AI for Sustainable Prevention of Autoimmunity in the Society) is an industry-healthcare partnership including Mainly AI, Lund University, Sahlgrenska University Hospital, Örebro University Hospital, The Swedish National Diabetes Register, Leading Health Care Foundation and Diamyd Medical, project coordinator. The project started in September 2021, has a duration of five years, and is financed by the Swedish innovation agency VINNOVA. ASSET has three main goals: Predict, Prevent and Implement. Predict: evaluate new algorithms based on Artificial Intelligence (AI) to be able to assess the individual risk of developing Type 1 Diabetes (T1D), and the likelihood of responding to different treatments. Data from cohort studies such as TEDDY (The Environmental Determinants of Diabetes in the Young), from Diamyd Medical's clinical trials with Diamyd® and from sources such as the National Diabetes Registry will constitute the initial training dataset for the algorithm. T1D will form the pilot project for the program, but the goal is extending the functionality to other indications including other autoimmune diseases that are strongly linked to T1D such as celiac disease (gluten intolerance) and autoimmune thyroiditis (inflammatory disease of the thyroid gland). Prevent: ASSET aims to be a test-bed for clinical development, with a pilot trial ongoing testing a precision medicine approach to early stage T1D. Implement: ASSET will study organizational, economic, and legal prerequisites and consequences of applying the approach as a tool for precision health in the Swedish health care system. The goal is to proactively manage obstacles that can slow down the implementation and spread of the innovations in the healthcare system. Website: https://www.asset.healthcare.se About Diamyd Medical Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company’s prospective European Phase IIb trial, where Diamyd® was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB. Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser. For further information, please contact: Ulf Hannelius, President and CEO Phone: +46 736 35 42 41 E-mail: ulf.hannelius@diamyd.com Diamyd Medical AB (publ) Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com The information was provided by the contact person above, for publication on November 15, 2024, 09:55 CET. Attachments: PDF version

Nil Medical has developed a medical vest to help seriously ill children and adolescents with intravenous drip stands to regain their mobility. The company developed the ergonomic medical vest to conceal fluids, pumps and tubing within the garments, allowing children to play and move without restrictions. Nil Medical is currently conducting a national quality-of-life study in collaboration with Swedish healthcare to introduce it to the international market. “I learned about the challenge faced by children who are willing and able to play but are restricted in their movement due to being attached to an IV stand. After visiting the pediatric cancer ward, I felt inspired to address this issue using a user-centered design methodology,” said Martin Hanberger, an industrial design student at Norrlands Universitetssjukhus. ”It feels incredible to finally have a finished product after so many years of development – especially when we see how much the children appreciate it. Making things easier for them has always been our driving force”. The company developed an early prototype and tested it without being connected to any treatment or IV bags. After, a group of specialists in design, product development and CE marking of medical devices collaborated with experienced staff in the pediatric oncology department to develop the Nil Medical Vestpack. Researchers on the project established requirements and conducted risk analyses to ensure the vest was safe and user-friendly. Interviews with patients, families and healthcare providers were also integral to the development process. “One of the young users said, ‘I want it to be nothing,'” Hanberger said. “The name Nil (English for ‘zero’) was thus born from the freedom of movement that our medical vest provides. Those who use it no longer have to be confined to drip stands; instead, they can move freely, safely, and securely.” Quality of life study Nil Medical is conducting a quality of life study in Sweden for the Vestpack in collaboration with Region Jönköping, Sahlgrenska University Hospital, and Norrlands Universitetssjukhus. The goal is to introduce a CE-marked infusion vest to the international market, giving children new possibilities and greater freedom of movement. The company is developing the system and testing it in collaboration with the Umeå Biotech Incubator. “Umeå Biotech Incubator has extensive business development expertise, a solid reputation and track record, and a broad network of contacts,” Hanberger said. “We are really looking forward to start collaborating with UBI.”

TUESDAY, Sept. 10, 2024 -- A European epilepsy drug could be an effective treatment for sleep apnea, a new study suggests. Patients who took sulthiame had few pauses in their breathing while asleep, as well as higher levels of blood oxygen, according to clinical trial results presented Tuesday at the European Respiratory Society annual meeting in Vienna. “This suggests that sulthiame could be an effective treatment for obstructive sleep apnea, especially for those who find they cannot use the existing mechanical treatments” like a CPAP machine , said researcher Jan Hedner from Sahlgrenska University Hospital and the University of Gothenburg in Sweden. Sulthiame has never been approved for use in the United States, but it is used in Europe to treat epilepsy. It appears to quell seizures by increasing blood levels of an established anticonvulsant called phenytoin. The drug also targets the respiratory system by inhibiting an enzyme called carbonic anhydrase, which stimulates upper airway muscles, researchers explained. For the study, researchers recruited nearly 300 people being treated for sleep apnea at hospitals in Spain, France, Belgium, Germany and the Czech Republic. None of the patients were using CPAP machines or mouthpieces to keep their airways open during sleep. Three-fourths of the participants were prescribed sulthiame at different dosage levels, and the remaining quarter took a placebo pill. Those taking the highest dose of sulthiame had 40% to 50% better breathing at night than those on placebo, based on different measures of sleep apnea, researchers said. Sulthaime patients also felt less sleepy during the daytime, researchers said. The drug produced mild to moderate side effects like pins and needles, headache, fatigue and nausea. “People taking sulthiame in the trial had a reduction in obstructive sleep apnea symptoms such as stopping breathing during the night and feeling sleepy during the day,” Hedner said in a meeting news release. “Their average levels of oxygen in the blood were also improved with the treatment.” However, Hedner said further clinical trials are needed to confirm these benefits before sulthaime can be widely adopted as a treatment for sleep apnea. Head of the ERS meeting, Sophia Schiza , noted this is one of the first studies to suggest that a drug could help with sleep apnea. Schiza was not involved in the research. “The results are promising,” Schiza, a professor of respiratory and sleep medicine at the University of Crete in Greece, said in a news release. “We need to continue testing sulthiame and other treatments to understand their long-term effects, including any side effects.” Because these findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.